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Abstract Intrachromosomal deletions linking Dpl expression
to the PrP promoter produce cerebellar degeneration that can
be abrogated by the introduction of wild-type PrP transgenes.
Since Dpl-like truncated forms of PrP are neuropathogenic in
mice and likewise counterbalanced by expression of PrPC we
asked whether naturally occurring mutant forms of human PrP
have Dpl-like attributes. Five PRNP missense mutations caus-
ing familial Creutzfeldt^Jakob disease (F-CJD) map to a heli-
cal region found in both PrPC and Dpl and result in amino acids
identical to conserved residues in Dpl. These F-CJD alleles may
cause mutant PrP to become a weak mimetic of Dpl structure
and/or function.
( 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The prion protein gene encodes a precursor to PrPSc, the
major structural component of prions. Prions are infectious
pathogens causing a number of disorders including scrapie
and BSE. Prion diseases manifest with diverse neuropatholo-
gies that may include spongiform degeneration, deposition of
extracellular amyloid deposits, and apoptosis [1^4]. Missense
mutations in the human Prnp gene cause inherited diseases
such as familial Creutzfeldt^Jakob Disease (F-CJD), Gerst-
mann^Stra«ussler Scheinker syndrome (GSS), and fatal fami-
lial insomnia (FFI) [5]. Prnp encodes a protein denoted PrPC
and in prion infections, PrPC is converted to PrPSc by tem-
plated refolding.
Although many mutations cause familial prion disease it is
not possible to predict a priori which missense mutations will
lead to a particular clinico-pathological phenotype. F-CJD is
a case in point. Although PRNP mutations were assumed to
cause thermodynamic destabilization of PrPC, F-CJD muta-
tions have only subtle e¡ects upon the thermal melting pro-
¢les of recombinant proteins [6,7]. Expressed in transfected
rodent cells, F-CJD alleles of Prnp neither engender bona
¢de protease-resistant PrPSc nor prion infectivity [8^11] and
transgenic mice expressing the E200K mutation do not devel-
op spontaneous neuropathology or prion infectivity [11,12].
These observations have led to the suggestion of pathogenicity
from altered ligand binding or interactions with membrane
components [13].
Doppel (Dpl) is a recently identi¢ed prion protein paralog
that, like PrPC, is GPI-anchored and has three K-helices. Dpl,
however, lacks the octapeptide repeat motifs present in PrP
and is unlikely to undergo conformational remodeling to a
protease-resistant form, or to facilitate remodeling of PrPC
[14^17]. Expression of Dpl in CNS neurons causes cerebellar
cell death and vacuolar change in white matter tracts but this
pathology is attenuated by expression of wild-type (wt) PrP
[18^20], presumably re£ecting competition between the activ-
ities of the two proteins. Remarkably, some mutant forms of
mouse PrP (PrPv32-121 and PrPv32-134) resembling Dpl also
cause ataxia marked by loss of Purkinje cells and apoptosis of
cerebellar granule cells. Like Dpl-associated ataxia, this is
prevented by addition of wt PrP transgenes [21,22]. These
observations led us to ask whether any human PRNP muta-
tions are pathogenic by virtue of acquiring Dpl-like character-
istics. In this report we examine the structural contexts of
pathogenic PRNP mutations. In most cases the mutations
causing one variety of familial prion disease introduce resi-
dues that are conserved in Dpl into PrP. Molecular dynamics
calculations, although no substitute for experimental struc-
tures, suggest that mutations that introduce Dpl-like features
into the sequences may introduce Dpl-like features into the
structures.
2. Materials and methods
Experimental structures of recombinant wt PrP, E200K PrP and
mouse Dpl were available from the Protein Data Bank (entries
1QLX, 1F07 and 1I17, respectively) (http://www.rcsb.org/pdb).
Molecular mechanics study of Dpl was carried out using the pub-
lished nuclear magnetic resonance (NMR) structure [14]. Mutations
were made in the PrP sequence using Insight II 98.0 (MSI, San Diego,
CA, USA). Side chain conformations for the mutated residues were
selected by examination of common rotomers from a side chain ro-
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tomer library. The rotomer producing the least steric clashes was
selected in each case. The structure was then soaked in an 8 AQ layer
of water and the charges on the protein set to values consistent with
an environmental pH of 7.0. Each structure was parameterized using
the CVFF force ¢eld [23] and energy minimized. The minimization
routine contained four sequential steps to allow bad steric contacts to
be resolved without unwanted distortions to the rest of the structure.
(1) All hydrogens were minimized using a steepest descents minimizer
until the maximum derivative was less than 0.0010000 kcal/AQ ; (2) all
side chains were minimized using a steepest descents minimizer while
the backbone was tethered with a force constant of 1000.0 kcal/AQ 2
until the maximum derivative was less than 0.50000 kcal/AQ ; and (3)
step 2 was repeated twice more using the conjugate gradients mini-
mizer while reducing the force constant to 100 kcal/AQ 2 and 0, respec-
tively. The structures were then subjected to 24 ps of molecular dy-
namics simulation at 300 K. All molecular mechanics studies were
carried out using a cut-o¡ distance of 30 AQ for the non-bond inter-
action calculation. These data were then used for structural alignment
(see main text).
Root mean square deviations (RMSDs) were calculated by a struc-
tural alignment procedure that seeks to determine a maximal common
well-¢tting substructure [24]. The method ¢rst tests all pairs of short
regions, adaptively, and then combines them to determine the largest
coherent substructure that retains the same topology. The calculations
are an adaptation of the methods described in Chothia and Lesk [25].
3. Results
3.1. F-CJD missense mutations recapitulate Dpl residues
Our objective was to test the hypothesis that some mutant
forms of PrP might be pathogenic by virtue of acquiring Dpl-
like properties. While primitive ‘PrP-like’ genes have been
reported in a variety of vertebrates [26,27], it is unclear
whether these organisms have prion gene complexes encoding
functional homologs of PrP and Dpl. Consequently we fo-
cussed upon mammals that both satisfy this criterion and
are susceptible to prion infections. A structure-based align-
ment of PrP and Dpl sequences was used to study the rela-
tionship between mutations in the human Prnp gene (PRNP)
and the Prnd gene encoding Dpl (Fig. 1). Our starting data-set
comprised all reported prion mutations lying within the cod-
ing regions of the PrP and Dpl (i.e. excluding sequences and
mutations lying within the N- and C-terminal signal peptides
that are removed during protein maturation). Cases de¢ned
by a single patient or where neuropathological analysis was
missing or inconclusive were excluded. In the case of GSS it
was not possible to undertake meaningful analyses for the
causative P102L, P105L and A117V mutations as these are
located within an area of PrP that has no cognate in Dpl [16].
Since the remaining GSS mutations (G131V, H178R, F198S,
D202N, Q212P and Q217R) do not result in the creation of
amino acid residues that are also conserved in Dpl, the hy-
pothesis that GSS PRNP alleles result in PrPC molecules more
Dpl-like than wt PrPC was rejected. Similarly, although stop
codon mutations at positions 145 or 160 are observed in con-
junction with neurodegenerative syndromes [28,29], these mu-
tant forms of PrP terminate before the K-helical region shared
between PrP and Dpl, and were also not considered further.
On the other hand, a relationship was noted for ¢ve F-CJD
mutations (V180I, E196K, E200K, V210I, and E211Q: Table
1).
In all cases the wt residue a¡ected by these mutations is
absolutely conserved between the PrP gene sequences pre-
sented in Fig. 1, as well as a compilation from a total of 46
mammals [30]. Of these, V180I, E196K, E200K and E211Q
result in amino acid changes that are exactly conserved in
human Dpl, while V210I involves an isoleucine conserved in
mouse, cow, sheep and rat Dpl proteins (Fig. 1). The sixth
well-studied F-CJD mutation D178N (more commonly found
in association with FFI when in cis to the Met 129 polymor-
phism) is represented by a glycine in Dpl and does not ¢t the
pattern of conservation.
Assignment of Dpl residues analogous to the six human
mutations was not based solely upon sequence alignment,
but also upon experimentally determined NMR structures of
recombinant PrP [31] and Dpl [14] (Fig. 1). Dpl residues
equivalent to the D178N and V180I mutations are absolutely
positioned by invariant conserved residues at V176 (human
PrP numbering scheme), C179, N181, and T183. E200, mu-
tated to lysine in the E200K F-CJD allele, is the N-terminal
residue of helix C in both PrP and Dpl, while V210 and E211,
mutated to I and Q respectively in F-CJD, are bracketed on
the N-terminal side by an invariant R208 residue and on the
C-terminal side by C214. The sixth instance comprises E196,
which is mutated to lysine in F-CJD and is positioned on the
C-terminal side by the aforementioned E200 residue.
Table 1
F-CJD mutations mimic features of Dpl
PRNP mutationsa Amino acid residue comparisons PrP/Dpl structural comparisons based upon molecular mechanics
simulatione
Analogous residue
in HuDplb
Other possible residuesd Allele modeled Residues super-
imposed
RMSD per
atom
Identical residues
in alignment
Wild type n.a.c n.a. Wild type 61 3.50 13
D178N (11) G(S) A, E, G, H, Y, V 178N 61 3.45 13
V180I (4) I (I) A, D, G, L, F 180I 59 2.26 12
E196K (3) K(K) A, D, E, G, Q, V, Stop 196K 71 2.38 15
E200K (63) K(K) A, D, E, G, V, Stop 200K 66 2.18 18
200K NMR structure 68 1.87 15
V210I (5) V(I) n.a. 210I 65 2.13 17
E211Q (3) Q(K) A, D, E, G, K, V, Stop 211Q 71 2.23 12
aNumber of reported cases in parentheses. See [5,46] for references to the individual mutations. Mutations de¢ned by a single case or where
neuropathological analysis was missing or inconclusive were not considered further. These include T188R, T188K, T188A, V203I, R208H and
M232R (see also main text).
bDpl consensus shown in brackets.
cn.a., not applicable.
dAlternative missense and nonsense substitutions arising from hypothetical single nucleotide changes in the relevant codon.
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Fig. 1. Structural alignment of human and mouse PrP with mouse, human, cow and sheep Dpl. The alignment of mouse PrP with mouse Dpl
is based on that of Mo et al. [14]. Residues identical to human PrP are highlighted in light blue. K-Helical regions (KA, KB, KBP and KC) are
indicated by red boxes and L-sheet by blue boxes. A kink in Dpl KB helix is indicated by a red arrow. Di¡erent CJD mutations under consid-
eration are indicated above the corresponding residues in human PrP. Yellow bars indicate a residue that changes in human PrP to the corre-
sponding CJD mutant residue in human Dpl, orange bars indicate a partial correspondence, and a red bar signi¢es no correspondence. The
numbering is with respect to human PrP. A region containing the octarepeats that has no equivalent in Dpl has been removed from this align-
ment for clarity. Green residues represent the discontinuous epitope that de¢nes the binding site for ‘protein X’ [36]. Consensus glycosylation
sites are in purple.
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3.2. PRNP and PRND gene sequences
To address a possible relationship arising as a trivial con-
sequence of gene sequence or codon usage we inspected nu-
cleotide sequences of the respective genes. Attempts to per-
form pair-wise ‘BLAST’ alignments of the complete open
reading frames of the human PrP (PRNP) and Dpl (PRND)
genes failed to reveal nucleotide homology (BLAST 2.2.1:
http://www.ncbi.nlm.nih.gov/blast), as noted previously [16].
A similar result was obtained when restricting the analysis
to DNA sequences encoding the KB-loop-KC regions and
KB/BP-loop-KC regions of PRNP and PRND, respectively.
To assess ‘micro’ sequence homology occurring in restricted
polynucleotide tracts, sequences were compiled for PRNP co-
dons prone to F-CJD mutations, their £anking 5P and 3P
codons, and the corresponding PRND nucleotides (data not
shown). Failure to de¢ne a constant relationship between the
nucleotide codons of V180, E196, E200 and E211 and their
equivalents in the human Dpl gene lead us to consider the
properties of the respective proteins.
3.3. Properties of E196K, E200K, and E211Q F-CJD
mutations
These F-CJD mutants all a¡ect (wt) glutamic acid residues
in human PrP, are perfect matches to the analogous human
Dpl residues, and result in a change to a basic residue. All are
closely juxtaposed and face upwards (E200 and E211) or out-
wards (E196) from the plane of the KB-loop-KC sub-domain
[13,31]. Residues with the analogous positions in mouse Dpl
(i.e. Dpl residues K125, K129 and K140) adopt similar dis-
positions with respect to the plane of the KBP-loop-KC sub-
domain (Fig. 2). To assess further similarities between Dpl
and mutant PrPC the NMR solution structure determined
for recombinant human E200K PrP [13] (RMSD=0.4^0.7
AQ ) was overlaid on the Dpl NMR structure. Overlay yielded
an RMSD of 1.87 AQ for the E200K PrP^Dpl comparison
versus 3.50 AQ for the wt PrP^Dpl comparison, emphasizing
the similarity between the E200K PrP and wt Dpl [32](bold
text in Table 1). Since NMR structures do not exist for the
E196K and E211Q proteins we modeled these mutations with
molecular dynamics simulation using Insight II 98.0 (MSI),
starting with the wt human PrP structure [31]. This modeling
paradigm has been validated experimentally [33]. We modeled
E200K in the same fashion as an internal control. Data pre-
sented in Table 1 give the total number of superposable CK
atoms and the number of superposed residues that contain
identical amino acids [32]. RMSD values of the superimpos-
able CK atoms of the E196K (2.36 AQ ), E200K (2.18 AQ ) and
E211Q (2.23 AQ ) proteins are lower than wt PrP (3.5 AQ ), in-
dicating that these structures are more Dpl-like. The RMSD
value for the modeled E200K^Dpl comparison is larger than
that for the experimentally determined structure E200K^Dpl
comparison (2.18 AQ versus 1.87 AQ ), suggesting that these mo-
lecular dynamics analyses may underestimate similarities with
Dpl.
3.4. Properties of the V180I and V210I F-CJD mutations
V180I and V210I are conservative changes in residues al-
most directly opposite one another on the inside faces of KB
and KC within PrPPs hydrophobic core [34]. When modeled
by molecular mechanics on the wt HuPrP NMR these analy-
ses revealed a substantial change in the RMSD values for the
V180I (2.26 AQ ) and V210I (2.13 AQ ) proteins compared to wt
HuPrP (3.5 AQ ), an alteration again in the direction of the Dpl
structure. Considered collectively, averaged RMSD values per
atom for V180I, E196K, E200K, V210I and E211Q were
2.24W 0.09 AQ , versus 3.50 and 3.45 AQ for wt PrP and
D178N PrP, respectively. The data also showed a tendency
for a greater number of superimposed residues and identical
residues in the alignment when again considering V180I,
E196K, E200K, V210I and E211Q mutant proteins versus
wt PrP and D178N PrP (Table 1).
Fig. 2. 3D models of human PrP, human PrP E200K and mouse Dpl. The protein backbone and structural motifs (K-helices and L-sheets) are
shown in light blue and gray. Selected residues are represented as ‘ball-and-stick’ molecules: red for acidic and blue for basic. The residues
under consideration are Glu196, Glu200 and Glu211 for human PrP; Glu196, Lys200 and Glu211 for human PrP E200K; and Lys125, Lys129
and Lys140 for mouse Dpl. The models are based on NMR coordinates obtained from the literature [13,14,31]. Images were generated with
MOLSCRIPT [45].
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3.5. F-CJD mutations and protein X
One explanation for pathogenic e¡ect of F-CJD mutations
is that they occur in a binding site for interactions with other
macromolecules. Since the notion of a binding site within the
K-helical domain of PrP has been proposed in the context of a
hypothetical protein X, the locations of F-CJD mutations
were compared with those of residues deemed important for
protein X binding [35,36]. The two sets of residues do not
overlap (Fig. 1, shown in green).
4. Discussion
We describe a relationship between a cluster of F-CJD mu-
tations and the structure of the Dpl protein [16], whereas no
similar trend was noted in a compilation of GSS mutations. In
four instances of F-CJD mutations perfectly recapitulate con-
served residues in the K-helical domain of human Dpl. If this
correlation holds true we would predict that ‘new’ F-CJD
missense alleles will map to PrPCPs KB-loop-KC region and
result in Dpl-like residues. Speci¢cally, we would predict that
mutations M205V, M206L, V209L arising from single nucle-
otide substitutions (as well as T188A, currently de¢ned by one
case) will cause F-CJD. At this stage, the D187N mutation
comprises the clear exception to the general rule. Whether the
D178N mutation causes CJD by a distinct mechanism, per-
haps related to an involvement of residue 178 in salt bridge
[37] with residues Asp178 and Arg164 (which have no exact
equivalent in Dpl) remains to be established. While N-termi-
nal insertions of PRNP also cause F-CJD, it is interesting to
note that interactions between the N-terminus of PrP and a
region of interest here, helixB, have been documented by pre-
vious NMR analysis [38].
4.1. Mutational and evolutionary considerations
In the context of recent gene duplications one might imag-
ine that parallelism could emerge between the pattern of mu-
tations in one gene versus the DNA sequence of the adjacent
gene. However, standard ‘BLAST’ algorithms failed to reveal
homology between mouse Prnp and Prnd. Even using an ar-
ti¢cial alignment considering the a¡ected codon plus one 5P
and one 3P codon no consistent relationship was noted be-
tween nucleotide sequences of the ¢ve selected F-CJD muta-
tions and the PRND nucleotide sequence (data not shown).
4.2. Mechanisms involving protein structure and function
End-stage F-CJD is marked by accumulation of protease-
resistant PrP and infectious prion titer [35,39^42], observa-
tions implying conformational reorganization of PrPC.
Whether this PrPSc arises from thermodynamic destabilization
or from a cell biological mechanism (e.g. altered metabolism
or tra⁄cking) is unclear, and current attempts to ‘model’ F-
CJD, and hence provide an assay to test pathogenic mecha-
nisms, have not been successful.
The correlation between F-CJD mutations and conserved
Dpl residues described herein suggests a new possibility,
namely that the mutations in this disease erode a boundary
between certain PrPC- and Dpl-associated functions. This no-
tion is compatible with two studies dealing with the expression
and copy-number of the wt PRNP allele in F-CJD. Decreased
expression of the wt allele has been implicated in disease onset
in E200K carriers, perhaps by reducing a protective e¡ect [43]
and homozygosity for E200K has been reported to hasten
disease onset [44]. These data parallel the protective e¡ect of
PrPC expression upon Dpl-mediated neurotoxicity [18]. Our
results suggest that studies to delineate the biochemical activ-
ities and binding partners of Dpl and PrPC, and the role of
the cluster of charged residues in PrPPs KB-loop-KC region
may provide insight into pathogenesis, as well as cell physiol-
ogy.
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